Financials
Financial year 2025
SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT from Aubel, company number BE0875441727, closed financial year 2025 with a result of € 28,056 after tax. For that financial year SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT recorded a gross margin of € 214,127 and equity of € 109,094. Compared with financial year 2024, the result moved from € 22,956 to € 28,056. Profitable, and profit is growing. The buffer shrank hard: equity is 60 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 3, 2026.
€ 109,094
▼ 60% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 28,056
▲ 22% vs 2024
Profit after tax over the fiscal year.
€ 174,712
▼ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 189,097 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 46,631
▼ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 174,070
▼ 44% vs 2024
€ 63,242 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 2,600
▼ 44% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,499
▼ 56% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 213,382 | € 199,212 | € 241,871 | € 214,127 | ▼ 11% |
| Profit after taxes | € 15,328 | € 24,863 | € 22,956 | € 28,056 | ▲ 22% |
| Equity | € 338,868 | € 293,303 | € 270,135 | € 109,094 | ▼ 60% |
| Total debts | € 357,545 | € 405,094 | € 387,588 | € 376,266 | ▼ 3% |
| Cash | € 67,467 | € 64,651 | € 180,731 | € 174,712 | ▼ 3% |
| Land & buildings | € 90,687 | € 78,204 | € 61,654 | € 47,112 | ▼ 24% |
| Retained profit | € 332,668 | € 287,103 | € 263,935 | € 102,894 | ▼ 61% |
| Dividend | € 0 | € 70,427 | € 46,124 | € 189,097 | ▲ € 142,973 |
| Bank debt | € 347,373 | € 322,329 | € 313,231 | € 174,070 | ▼ 44% |
| Balance sheet total | € 702,835 | € 707,296 | € 664,042 | € 489,099 | ▼ 26% |
Key figures of SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT?
What happened at SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 28,056 (▲ 22% vs 2024). Source: NBB ↗
- New establishment in Aubel. KBO
- Start of the company according to the CBE. KBO
In short
From € 15,328 profit in 2022 to € 28,056 profit in 2025.
Paid € 47,744 in corporate taxes since 2022.
Best year ever: 2025, with € 28,056 profit.
Paid out € 305,648 in dividends to the owners in total.
Management
Behind SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT are Stanislas LAURENT and Annelore BARBEAUX.
Directors
According to the 2025 annual accounts
Stanislas LAURENT
Director
Annelore BARBEAUX
Director
Establishments
Establishment units
Physical locations of this company
Rue des Bocages 23
4880 Aubel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0875.441.727
- VAT number
- BE 0875.441.727
- Registered office
- Rue des Bocages 23, 4880 Aubel
- Names & denominations
- SURGICAL AND MEDICAL ONCOLOGY DEVELOPMENT · SAMOND
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 August 2005
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Activiteiten van medisch specialisten